相约JPM，报名开启！2026中国FIC创新与合作峰会

过去十年，中国创新药研发管线数量呈现爆发式增长，已成为全球新药研发体系中不可或缺的一环。在双特异性抗体、ADC等前沿技术领域，中国已形成具备全球竞争力的研发集群，持续推动跨境交易活跃增长。2025年，中国创新药对外许可总额突破1000亿美元，达2024年同期的两倍。然而，目前仅有约10%的新药管线进入交易视野，更多高价值资产仍待全球合作伙伴共同发掘。

中国创新药的崛起并非偶然，而是政策引导、人才集聚、资本支持与产业升级共同驱动的必然结果。这一体系性优势，使中国在新药研发效率、临床执行能力及前沿赛道布局方面展现出卓越潜力。

在此关键历史时刻，中关村FIC创新药战略发展联盟（） 肩负使命，将于2026年JPM大会期间，隆重主办“2026中国FIC创新与合作峰会” 。这不仅仅是一场会议，更是一次中国生物科技力量的集体亮相，一个为全球伙伴精心打造的顶级合作平台。

本届峰会将系统解读中国创新药的发展动因、现状与未来趋势，并精选一批在全球范围内具有领先研发进度、高度临床契合度及显著交易价值的创新药项目进行路演，为与会者提供评估中国创新实力、发掘高价值合作机遇的重要窗口。

一、会议基本信息

主办机构：中关村FIC创新药战略发展联盟

时 间：2026年1月11日

地 点：美国加州旧金山市中心凯悦酒店

会议人数：400人

注册费用：免费报名+审核

二、会议日程

09:00-09:20 致辞

09:20-09:40主题演讲

中国创新药十年10年发展

09:40-10:20主题演讲

中国生物科技创新的全球趋势

10:10-10:20 茶歇

自由交流

10:20-10:40 主题报告

中国创新药对外授权交易趋势与数据洞察

10:40-11:00 主题报告

小核酸创新药的中国力量

11:00-12:00圆桌讨论

中国FIC管线的创新前沿展望

12:00-13:30 自助午餐

13:30-13:40 ZFIC联盟介绍

13:40-14:00主题报告

创新药生态的“通关指南”：人才、政策与资本的高效协同

14:00-16:00 项目路演

16:00-17:00 圆桌讨论

寻找下一个重磅药物：立项、速度与价值

17:00-18:00圆桌讨论

携手向前：构建创新药全球新生态

2026 China FIC Innovation and Collaboration Summit

Over the past decade, the number of innovative drug pipelines in China has experienced explosive growth and has become an important part of the global innovative drug landscape. In the meanwhile, transaction activities over Chinese innovative drugs have continued to be active, with cross-border transactions emerging continuously. In particular, China has formed R&D clusters with global competitiveness in emerging technology fields such as bispecific antibodies and ADCs. In 2025, the total amount of cross-border licensing of Chinese innovative drugs exceeded 100 billion US dollars, doubling the scale of the same period in 2024. Even so, only about 10% of the new drug pipelines in China have been involved in transactions. More high-value tradable pipeline assets are still waiting to be explored for cooperation with global partners.

In light of this, the Zhongguancun FIC Innovative Drug Strategic Development Alliance (ZFIC Alliance) will hold the "2026 China FIC Innovation and Collaboration Summit" during the 2026 JPM Conference, aiming to build an efficient communication platform for international pharmaceutical companies, investment institutions, and Chinese biotech enterprises.

This summit will provide a comprehensive data-driven interpretation of driving factors, current status, and future trends of Chinese innovative drugs’ explosive growth, and offering participants a full and authentic view of the Chinese innovative drug landscape. In addition, the summit will organize roadshows for a number of selected Chinese innovative drug pipelines of globally leading development status, critical clinical relevance, and significant underlying transaction values. The event will be a window to discover high-value strategic cooperation opportunities over China's most innovative therapeutic assets.

Time: January 11, 2026

Location: Hyatt Regency San Francisco Downtown SOMA

Agenda

8:30-9:00 Registration

9:00-9:20 Opening Remarks

9:20-9:50 Keynote Speech

10 Years of Development of China's Innovative Drugs

9:50-10.10 Keynote Speech

Trends in China's Biotech Innovation

10:10-10:20 Coffee Break

10:20-10:40 Keynote Speech

Trends and Data Insights of China's Innovative Drug Out-Licensing Transactions

10:40-11:00 Keynote Speech

Highlights of China’s innovation in Oligonucleotide Innovative Drugs

11:00-12:00 Panel Discussion

Outlook of China's FIC Pipeline

12:15-13:30 Buffet Lunch

13:30-14:00 Keynote Speech

The "Rulebook" for the Innovative Drug Ecosystem: Efficient Synergy of Talent, Policy, and Capital

14:00-16:00 Roadshow

16:00-17:00 Panel Discussion

Finding the Next Blockbuster Drug: Project Planning, Speed, and Value

17:00-18:00 Panel Discussion

Moving Forward Together: Building a New Global Ecosystem for Innovative Drugs